Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
December 09, 2011 18:30 ET
|
Transition Therapeutics Inc.
TORONTO, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX:TTH) (Nasdaq:TTHI) today announces that Mr. Elie Farah, the Company's President and Chief Financial Officer,...
Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results
December 01, 2011 16:01 ET
|
Transition Therapeutics Inc.
TORONTO, Dec. 1, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics for...
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST
November 29, 2011 17:11 ET
|
Transition Therapeutics Inc.
TORONTO, Nov. 29, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Thursday, December 1, 2011 at 4:30 P.M....
Transition Therapeutics Completes US$5 Million Private Placement
November 22, 2011 17:32 ET
|
Transition Therapeutics Inc.
TORONTO, Nov. 22, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced the closing of its previously disclosed private...
Transition Therapeutics Announces US$5 Million Private Placement
November 21, 2011 06:31 ET
|
Transition Therapeutics Inc.
TORONTO, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced that it has entered into agreements to issue 3,703,703...
Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
September 27, 2011 07:01 ET
|
Transition Therapeutics Inc.
TORONTO, Sept. 27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced that Phase 2 clinical study data of ELND005 in mild to...
Transition Therapeutics Announces Fiscal 2011 Year End Financial Results
September 19, 2011 16:01 ET
|
Transition Therapeutics Inc.
TORONTO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics...
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
September 16, 2011 17:01 ET
|
Transition Therapeutics Inc.
TORONTO, Sept. 16, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Monday, September 19, 2011 at 4:30 P.M....
Transition Therapeutics to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
September 09, 2011 08:01 ET
|
Transition Therapeutics Inc.
TORONTO, Sept. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that Elie Farah, President and Chief Financial Officer of...
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
July 15, 2011 16:15 ET
|
Transition Therapeutics Inc.
TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in...